Answers are grounded in this paper and cite their sources.
Background Early medulloblastoma recurrence remains difficult to detect using conventional imaging and cerebrospinal fluid (CSF) cytology. As such, a 2025 update to the National Comprehensive Cancer Network Clinical Practice Guidelines recommended CSF liquid biopsy for the detection of medulloblastoma molecular markers to inform disease detection and surveillance. Case Summary Belay Diagnostics CSF liquid biopsy testing for clinically actionability genomic variants and chromosomal alterations was used in diagnostic work-up and/or monitoring of three cases of recurrent pediatric medulloblastoma from a single institution. Tumor-derived genomic alterations were identified in all three cases. The genomic profiles reported by Belay Diagnostics testing provided evidence of recurrence, confirmed leptomeningeal disease, and informed treatment decisions. Conclusions These findings demonstrate the clinical utility of CSF liquid biopsy as a sensitive, minimally-invasive tool that complements standard surveillance to detect recurrent medulloblastoma and guide clinical management.
No takes yet. Share an insight, caveat, or question.
Maher et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: